Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GENZYME - THE KING OF THE BIOTECHS -- Ignore unavailable to you. Want to Upgrade?

To: Andreas Helke who wrote (318)	7/29/1998 1:27:00 PM
From: Vector1	Respond to of 410

Andreas, One of the keys for anti-adhesion products is convincing the insurance companies that it saves them money in the long run. I believe the company is trying to create this data. Sometime the insurance cos can be shortsighted. The decision on whether to buy CHAI depends on whether they can penetrate the market. If the market is simply not receptive to an anti adhesion product then they should cut their losses and sell the entire surgical division. V1